urothelial carcinoma Archives -

NICE has recommended routine use of Bristol-Myers Squibb’s Opdivo for the adjuvant treatment of some patients with urothelial

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

https://pharmaphorum.com/news/bms-opdivo-gets-nhs-use-as-adjuvant-bladder-cancer-therapy/

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar’s bempegaldesleukin a companion drug to its

End of the line for BMS, Nektar’s bempegaldesleukin/Opdivo alliance

https://pharmaphorum.com/news/end-of-the-line-for-bms-nektars-bempegaldesleukin-alliance/

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance

Scotland backs Bavencio for bladder cancer after NICE says no

https://pharmaphorum.com/news/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no/

Merck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer

NICE says no to Merck Serono’s Bavencio in bladder cancer

https://pharmaphorum.com/news/nice-says-no-to-merck-seronos-bavencio-in-bladder-cancer/

Pfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

https://pharmaphorum.com/news/merck-pfizer-get-eu-nod-for-bavencio-as-bladder-cancer-maintenance/

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1

AZ stakes its claim in immunotherapy with bladder cancer filing

https://pharmaphorum.com/news/az-stakes-claim-immunotherapy-bladder-cancer-filing/

urothelial carcinoma